Engineered tRNA Helps Bypass Nonsense Mutations in Cystic Fibrosis

A University of Toronto-led team has developed a nonviral RNA strategy for cystic fibrosis caused by nonsense mutations—genetic errors that insert a premature stop signal into the instructions for making a protein. Instead of editing the CFTR gene, the researchers supplied engineered suppressor transfer RNA (sup-tRNA) designed to read through that faulty signal and help cells finish producing full-length CFTR protein. 1

The work was demonstrated in bronchial epithelial cells, mouse models, and patient-derived cystic-fibrosis organoids. It is a promising preclinical platform, not yet a proven human therapy.

The problem: a premature stop signal cuts CFTR short

A nonsense mutation causes the cell’s protein-making machinery to stop translation too early. In CFTR, that can leave cells with little or no full-length protein capable of functioning as a chloride channel.

That distinction matters for current cystic-fibrosis medicines. CFTR modulators are designed to improve the folding, trafficking, or activity of CFTR that the cell has produced; they cannot fully compensate when a premature stop signal prevents enough complete protein from being made. The study therefore focuses on a subgroup of patients with CFTR nonsense mutations who may not respond adequately to modulators alone. 12

Nonsense mutations are estimated to account for about 11% of inherited genetic disorders. Because the same type of translation error appears across many genes, a safe readthrough strategy could potentially be adapted beyond cystic fibrosis. 2

How suppressor tRNA bypasses the mutation

Transfer RNA normally matches messenger-RNA codons with amino acids during translation. The researchers engineered suppressor tRNAs with anticodons that recognize a premature termination codon in mutant CFTR messenger RNA.

When the suppressor tRNA reaches that erroneous stop signal, it inserts an amino acid instead of allowing translation to end. The ribosome can then continue reading the message and produce a full-length CFTR protein. In effect, the therapy bypasses the misplaced stop instruction rather than repairing the DNA sequence itself. 14

Because the RNA is not intended to permanently alter the genome, the approach is transient. If it advances clinically, repeat administration would likely be needed, although the required interval will depend on how long activity persists and how safely the therapy can be redosed.

Why the chemical modification mattered

Unmodified suppressor tRNAs face several obstacles: they must remain stable long enough to work, be loaded with the correct amino acid, efficiently promote readthrough, and avoid provoking an excessive innate immune response.

The team introduced a site-specific chemical modification found naturally in tRNA. The reported effects included improved aminoacylation, more efficient premature-stop readthrough, longer functional activity, and reduced innate immune activation. The available evidence does not identify the modification by name, so it should not be assumed to be a particular compound such as pseudouridine. 158

This engineering addressed more than one bottleneck at once. A tRNA that reads through a stop codon but is poorly charged, rapidly degraded, or strongly immunostimulatory would have limited therapeutic value.

Why delivery was designed for the lungs

The researchers also developed lipid nanoparticle formulations tailored to the unusually structured tRNA cargo. They screened formulations for delivery performance and administered the selected particles by inhalation, a route intended to concentrate the RNA in lung tissue and airway cells. 18

This is a nonviral delivery system: the lipid nanoparticles carry the therapeutic RNA into cells but do not rely on a viral vector or permanently insert a corrected gene. Earlier work had already shown that LNP-delivered suppressor tRNAs could restore functional protein production in mouse models, providing a foundation for the newer cargo-specific and pulmonary design. 4

What the models showed

The combined sup-tRNA and inhaled-LNP treatment restored CFTR protein production and associated channel function in several experimental settings:

• Human bronchial epithelial cells: the treatment promoted readthrough of the premature termination codon and restored production of full-length CFTR.
• Mouse cystic-fibrosis models: inhaled delivery reached the lungs and produced prolonged activity, reported at up to roughly 40 days in mice. That duration is preclinical and cannot be assumed to apply to people. 16
• Patient-derived organoids: the approach restored full-length CFTR in an organoid carrying four CFTR variants, including two nonsense variants. 18

The organoid findings also exposed an important limitation. In that model, the newly produced CFTR still required the corrector and potentiator combination elexacaftor–tezacaftor–ivacaftor, commonly known as Trikafta, for optimal folding, trafficking, and channel activity. The likely treatment logic in at least some mutations is therefore restore protein production first, then improve the rescued protein’s behavior—not necessarily replace CFTR modulators altogether. 13

What the approach could mean beyond cystic fibrosis

Suppressor tRNAs can, in principle, be designed to recognize each of the three stop codons. That creates a mutation-class platform: the same general strategy might be adapted to different diseases if researchers can select the appropriate tRNA, insert a suitable amino acid, deliver enough cargo to the relevant tissue, and preserve normal translation.

The opportunity is broad, but it is not automatic. Different proteins may tolerate different amino-acid substitutions, and a protein rescued from a premature stop may still misfold or require a stabilizing drug. Delivery is also organ-specific. A formulation optimized for inhaled lung delivery would not necessarily work for the liver, muscle, brain, or kidney; each tissue may require a different nanoparticle and administration route. 34

Safety questions still stand between the models and a treatment

The central translational questions include:

• Could the suppressor tRNA cause unintended readthrough at normal stop codons?
• Could altered translation produce harmful off-target proteins or incorrect amino-acid substitutions?
• Is the formulation safe and effective after repeated inhaled doses?
• How widely does it distribute through the lungs, and how long does it remain active?
• Could lipid nanoparticles or the RNA trigger inflammation or other immune reactions?

Outside reporting has highlighted dose-dependent inflammation in mice and the broader respiratory-safety concerns associated with inhaled LNP approaches. Those issues require careful testing before the therapy can be considered clinically established. 613

The study’s main advance is the combination of tRNA chemistry and organ-targeted delivery. By improving readthrough, durability, amino-acid loading, and tolerability while directing the cargo to the lungs, the researchers restored meaningful CFTR production and function across preclinical and patient-derived models. The next challenge is determining whether that effect can be reproduced safely, repeatedly, and predictably in people—and whether different CFTR mutations will require combination treatment to make the rescued protein work.